Skip to content Skip to footer
Subscribe Now
PharmaShots Interview SOTIO Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced Metastatic Solid Tumors
VIEWPOINTS

PharmaShots Interview: SOTIO’ Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced/Metastatic Solid Tumors

In an interview with PharmaShots, Richard Sachse, Chief Medical Officer & Managing Director at SOTIO shared his views on the data of SOT101 in the P-I/Ib (AURELIO-03) study for the treatment of advanced/metastatic solid tumors Shots: The P-I/Ib (AURELIO-03) study evaluates SOT101 as monothx. & in combination with pembrolizumab in patients with advanced/metastatic solid tumors The results showed that 13 patients…
April 6, 2022

Read more

Viewpoints_Garret Hampton
VIEWPOINTS

PharmaShots Interview: Thermo Fisher Scientific Garret Hampton Shares Insight on the Multiyear Agreement with AstraZeneca for NGS-based CDx

In an interview with PharmaShots, Garret Hampton, President of Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific share his views on multiyear agreement with AstraZeneca to co-develop NGS-based CDx for targeted therapies Shots: The collaboration will expand AstraZeneca’s portfolio of targeted therapies for cancer & other diseases. Thermo Fisher currently offers the NGS CDx solution which is approved…
November 9, 2021

Read more